In3 Measuring Innovation
-
Upload
michael-morrison -
Category
Technology
-
view
394 -
download
0
description
Transcript of In3 Measuring Innovation
![Page 1: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/1.jpg)
Measuring Innovation – a brief introduction to the REMEDiE
project
Michael MorrisonInnovative Health Technologies: health systems in transition
Barcelona 26-7 November 2009
![Page 2: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/2.jpg)
04/10/23 2
INTRODUCTION
REMEDiE: Regenerative
Medicine
in Europe
“Emerging Needs and Challenges in a Global Context”
FP-7 Funded European project Multi-partner, multi-country endeavour Work Package 1 = SATSU
![Page 3: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/3.jpg)
04/10/23 3
INTRODUCTION
What is Regenerative Medicine? A heterogeneous domain incorporating the
biological sciences, engineering, materials science, medicine, and surgery.
The aim of regenerative medicine is the restoration, maintenance, or enhancement of tissue, cell and organ function.
Materials: living tissue or cells, genes, and structural ‘scaffolding’ components including collagen matrices and synthetic polymers.
![Page 4: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/4.jpg)
04/10/23 4
INTRODUCTION
“This WP will map current ways in which capital is being employed within Europe and compare this to the global economy of regenerative medicine”
REMEDiE Final Project Description
“bio-capital’ research is nevertheless hampered by the low levels of financial accountability […] the traceability of private ‘bio-capital’ is limited and there are no clear figures to tell how much investment activity has been going on”
Beyond the Bull Market presentation (Kewell, 2009)
![Page 5: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/5.jpg)
04/10/23 5
INTRODUCTION
SO WHAT CAN WE MEASURE? ‘Universe’ of European commercial
companies involved in Regen Med Patents and the intellectual property
associated with Regen Med
![Page 6: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/6.jpg)
EUROPEAN REGEN MED
COMPANY UNIVERSE
![Page 7: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/7.jpg)
04/10/23 7
EUROPEAN RM COMPANY UNIVERSE
72 active regenerative medicine companies in Europe
UK (27) and Germany (17) have by far the greatest concentration [Sweden =6]
30 companies 5-10 years old and 32 10+ yrs
Majority of companies have <100 staff
![Page 8: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/8.jpg)
04/10/23 8
EUROPEAN RM COMPANY UNIVERSE 2#
Commerical Focus: Cell Therapy
10
16
26
3 3
6
13
19
32
05
101520253035
StemCell
Non-stemCell
All CT
Autologous Allogenic Total
Commerical Focus: Non-cell Therapy
8
22 25
55
0102030405060
No. of Companies
![Page 9: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/9.jpg)
04/10/23 9
EUROPEAN RM COMPANY UNIVERSE 3#
Purpose of the survey is to provide context for the selection of a small number of case studies for in-depth analysis
Different indices not just an overview but can be used to select case studies that exemplify different aspects of commercial European regenerative medicine
Can illustrate using Gene Therapy
![Page 10: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/10.jpg)
04/10/23 10
EUROPEAN RM COMPANY UNIVERSE 4#
NAME LOCATION SIZE AGE (years)
DISEASE FOCUS
PRODUCTS ON MARKET
Amsterdam Molecular Therapeutics
Netherlands Small 5-10 Protein deficiency No
Ark Therapeutics
UK Small- medium 10+ Vascular disease and cancer
Five non-RM products, mainly wound dressings
Arthrogen BV Netherlands Small <5 Rheumatoid Arthritis
No
Diamyd Medical AB
Sweden Small 10+ Chronic pain Main program is therapeutic vaccine for diabetes
MolMed Italy Small 10+ Cancer No
Mologen AG Germany Small 10+ Cancer No
Oxford Biomedica
UK Small 10+ Cancer, Parkinson's’
No
Transgene France Medium 10+ Cancer vaccines No
![Page 11: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/11.jpg)
04/10/23 11
SUMMARY
Company Universe gives:What’s out thereWhat they’re doing (or not)Characterisation of regenerative medicine sub-sectors
![Page 12: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/12.jpg)
PATENT DATA:
Index of Innovation?
![Page 13: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/13.jpg)
04/10/23 13
PATENT DATA & THE WORK PACKAGE 2#
Patent analysis can provide: A measure of the size and growth rate of a
biotechnology sub-field (Reiss & Strauss,1998; Bergman & Graff, 2007)
An index of innovative activity (Nelson, 1998)
Trace the process of ‘turning science into business’ in the bioeconomy (Oldham & Cutter, 2006)
![Page 14: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/14.jpg)
04/10/23 14
PATENT DATA & THE WORK PACKAGE 3#
![Page 15: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/15.jpg)
04/10/23 15
PATENT DATA & THE WORKPACKAGE 4#
![Page 16: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/16.jpg)
04/10/23 16
PATENT DATA & THE WORKPACKAGE 5#
Trends in patent activity over time Trends in choice of patent office and
applicants Most active institutions, sectors, nation
states and regions Provide a systematic overview of activity
across and within regenerative medicine sub-fields
![Page 17: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/17.jpg)
04/10/23 17
Data use?
Private data – hard to unpack company claims
Marshalled data – commercial data, existing surveys
Finding what can be measured Creating definitions? Of regenerative
medicine and of innovation
![Page 18: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/18.jpg)
04/10/23 18
REFERENCES
Bergman, K. & Graff, G.D. (2007) The global stem cell patent landscape: implications for efficient technology transfer and commercial development. Nature Biotechnology 25 pp419-424
Martin, P., Hawksley, R. & Turner A. (2009) The commercial development of cell therapy – lessons for the future? University of Nottingham, Nottingham.
Nelson, J. (1998) Analysis of patenting within gene therapy. Expert Opinion on Therapeutic Patents, 8(11) pp1495-1505
![Page 19: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/19.jpg)
04/10/23 19
REFERENCES
Oldham, P. & Cutter, A.M. (2006) Mapping global status and trends in patent activity for biological and genetic material. Genomics, Policy & Society 292) pp62-91
Reiss, T. & Strauss, E. (1998) Gene therapy - the dynamics of patenting worldwide. Expert Opinion on Therapeutic Patents, 8(2) pp173-179
![Page 20: In3 Measuring Innovation](https://reader035.fdocuments.net/reader035/viewer/2022062616/54954da3b47959076a8b45a2/html5/thumbnails/20.jpg)
04/10/23 20
REFERENCES
Additional Material Kewell, B. (2009) Beyond the ‘Bull Market’:
Biocapital and regenerative medicine in a changing financial world. Presented at Beyond Pattison - Challenges for Stem Cell Translation and Policy, May 7-8, London.